全球多形性胶质母细胞瘤治疗市场 - 市场规模、份额、成长分析：按类型、按应用划分 - 产业预测（2023-2030）

Global Glioblastoma Multiforme Treatment Market Size, Share, Growth Analysis, By Type(Surgery, Radiation Therapy), By Application(Newly Diagnosed glioblastoma multiforme treatment, Recurrent glioblastoma multiforme treatment) - Industry Forecast 2023-2030

出版日期: 2023年10月24日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计2021年全球多形性胶质母细胞瘤治疗市场规模将达23亿美元，2022年将达25亿美元。预计该市场在预测期（2023-2030年）将以8.9%的年复合成长率成长，到2030年将达到49.5亿美元。

近年来，由于全球多形性胶质母细胞瘤治疗病例数量的增加以及对有效治疗方案的需求不断增长，全球多形性胶质母细胞瘤治疗市场出现了显着增长。多形性胶质母细胞瘤的罹患率不断增加，加上可用的治疗选择有限，迫切需要创新和有效的治疗方法，从而推动市场成长。我是。医学研究和技术开发的进步正在促进治疗多形性胶质母细胞瘤的新治疗方法的开发。市场正在向个人化医疗方法转变，重点是标靶治疗和免疫疗法。标靶治疗，例如酪胺酸激酶抑制剂和单株抗体，旨在破坏多形性胶质母细胞瘤治疗进展中涉及的特定分子途径。免疫疗法，包括免疫检查点抑制剂和嵌合抗原受体（CAR）T细胞疗法，利用人体的免疫系统来辨识并消灭癌细胞。这些进步显着改善了治疗结果，并推动了多形性胶质母细胞瘤治疗市场的成长。

多形性胶质母细胞瘤（一种侵袭性脑瘤）发生率的增加是市场的关键驱动力。随着全球多形性胶质母细胞瘤的盛行率持续上升，越来越需要开发有效的治疗方案。这推动了对多形性胶质母细胞瘤治疗的需求并推动市场成长。

治疗多形性胶质母细胞瘤的费用是患者的经济负担，主要是由于与手术、放射线治疗、化疗和支持性护理相关的费用。高治疗成本会阻碍患者获得先进治疗并影响治疗的承受能力。此外，报销政策在确定患者获得治疗的机会方面发挥关键作用，从而影响市场成长。

本报告研究了全球多形性胶质母细胞瘤治疗市场，并提供了市场概述，包括按类型、应用、地区和参与市场的公司概况分類的趋势。

主要企业简介
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Bristol Myers Squibb Company
- Eli Lilly and Company
- AbbVie Inc.
- Pfizer Inc
- Tocagen Inc.
- Kazia Therapeutics Limited
- DelMar Pharmaceuticals, Inc.
- Arbor Pharmaceuticals, LLC
- BTG International Ltd
- Mundipharma International Limited
- Northwest Biotherapeutics
- Orbus Therapeutics Inc.
- VBL Therapeutics
- GT Medical Technologies, Inc.
- Oncolys Biopharma Inc.
- Tocagen
- ValiRx Plc

简介目录

Product Code: SQMIG35D2105

Global Glioblastoma Multiforme Treatment Market size was valued at USD 2.3 billion in 2021 and is poised to grow from USD 2.5 billion in 2022 to USD 4.95 billion by 2030, growing at a CAGR of 8.9% in the forecast period (2023-2030).

The global market for glioblastoma multiforme treatment has witnessed substantial growth in recent years, driven by the increasing incidence of glioblastoma multiforme treatment cases worldwide and the growing demand for effective treatment options. The increasing incidence of glioblastoma multiforme treatment, coupled with the limited treatment options available, has created a pressing need for innovative and effective therapies, thereby fueling market growth. Advancements in medical research and technology have contributed to the development of novel treatment modalities for glioblastoma multiforme treatment. The market has witnessed a shift towards personalised medicine approaches, with a focus on targeted therapies and immunotherapies. Targeted therapies, such as tyrosine kinase inhibitors and monoclonal antibodies, aim to disrupt specific molecular pathways involved in glioblastoma multiforme treatment progression. Immunotherapies, including immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, harness the body's immune system to recognize and destroy cancer cells. These advancements have significantly improved treatment outcomes and have spurred the growth of the glioblastoma multiforme treatment market.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Glioblastoma Multiforme Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glioblastoma Multiforme Treatment Market Segmental Analysis

The global glioblastoma multiforme treatment market is segmented by type, application, and region. Based on type, the market can be segmented into Surgery, Radiation Therapy, Chemotherapy and Targeted Therapy. Based on application, the market is segmented into Newly Diagnosed glioblastoma multiforme treatment, Recurrent glioblastoma multiforme treatment, Palliative Care, Clinical Trials and Paediatric glioblastoma multiforme treatment. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Glioblastoma Multiforme Treatment Market

Increasing Incidence of Glioblastoma Multiforme

The increasing occurrence of glioblastoma multiforme, an aggressive brain cancer, is a significant driver of the market. As the prevalence of glioblastoma multiforme treatment continues to rise worldwide, there is a growing need for the development of effective treatment options. This drives the demand for glioblastoma multiforme treatment treatments and fuels market growth.

Restraints in the Global Glioblastoma Multiforme Treatment Market

High Treatment Costs

The cost of glioblastoma multiforme treatment poses a financial burden for patients, primarily due to the expenses associated with surgery, radiation therapy, chemotherapy, and supportive care. The high treatment costs can impede patient access to advanced therapies and impact the affordability of treatments. Furthermore, reimbursement policies play a crucial role in determining patient access to these treatments, thereby influencing market growth.

Market Trends of Global Glioblastoma Multiforme Treatment Key

Increasing Use of Targeted Therapies: Targeted therapies are designed to target specific molecules involved in the growth and spread of glioblastoma multiforme treatment cells. These therapies have shown promise in improving the survival rates of patients with glioblastoma multiforme treatment.
Development of New Immunotherapies: Immunotherapies are designed to boost the body's immune system to fight cancer cells. These therapies are still in the early stages of development, but they have shown promise in treating glioblastoma multiforme treatment.
The Increasing Demand for Personalised treatment: Personalised treatment is tailored to the individual patient's tumour profile. This approach has the potential to improve the efficacy and safety of treatment for glioblastoma multiforme treatment patients.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Glioblastoma Multiforme Treatment Market by Type
- Market Overview
- Surgery
- Radiation Therapy
- Chemotherapy
- and Targeted Therapy.
Global Glioblastoma Multiforme Treatment Market by Application
- Market Overview
- Newly Diagnosed glioblastoma multiforme treatment
- Recurrent glioblastoma multiforme treatment
- Palliative Care
- Clinical Trials and Pediatric glioblastoma multiforme treatment.
Global Glioblastoma Multiforme Treatment Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Merck & Co., Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- F. Hoffmann-La Roche Ltd (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Novartis AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bristol Myers Squibb Company (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Eli Lilly and Company (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- AbbVie Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Pfizer Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Tocagen Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Kazia Therapeutics Limited (Australia)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- DelMar Pharmaceuticals, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Arbor Pharmaceuticals, LLC (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- BTG International Ltd (United Kingdom)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Mundipharma International Limited (United Kingdom)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Northwest Biotherapeutics (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Orbus Therapeutics Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- VBL Therapeutics (Israel)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- GT Medical Technologies, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Oncolys Biopharma Inc. (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Tocagen (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- ValiRx Plc (United Kingdom)
Company Overview
Business Segment Overview
Financial Updates
Key Developments